Scholars Central

Conference abstract

Transgenic blood proteins: An abundant source for next generation therapies with worldwide availability

Authors: William Velander

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The use of cultured animal cells to produce complex human proteins has almost eliminated the risk of disease transmission as experienced from biotherapeutics originally derived from human blood. Prime examples of proteins having exceptionally complex structure and functions that are now available as recombinant analogues are Factor VIII and Factor IX which are used to treat hemophilia A and B, respectively. However, these are limited in supply worldwide. Notably, significant amounts of factor are needed to induce tolerization in response to adverse, titrating antibodies that occur after intravenous administration. Thus, the next goal of biotechnology is to provide non-intravenous therapies that simultaneously achieve immune tolerization with pharmacokinetically longer lasting activity. A quantum increase in abundance is needed to enable these advances which would both increase the quality of patient life and make treatment more affordable. Importantly, the US FDA and EMEA have both approved transgenic (tg) animal-derived therapies thus establishing a regulatory precedent, albeit for less complex proteins such as tg-antithrombin III in the milk of goats. Both tg-Factor VIII (tg-FVIII) and tg-Factor IX (tg-FIX) made from the milk of pigs are on the cusp of being next generation Biotherapeutics that might achieve a quantum leap in supply to counter the low bioavailability that nonintravenous therapies such as buccal delivery inherently possess. Here, we presenta review of the biochemical characterization of tg-FVIII, tg-FIX, and tg-fibrinogen as well as preclinical animal studies in mice, dogs and pigs which show promising physiologic function.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “William Velander”